Renephra, a Manchester, UK-based developer of a medical device to treat patients with chronic oedema and fluid overload, raised a funding round of undisclosed amount.
Backers included Deepbridge Capital and Catapult Ventures.
The company intends to use the funds to support a research study to demonstrate the feasibility of the technology in patients with severe oedema, including those with heart failure.
Led by Dr Idalia Dawidowska, CEO, Renephra has advanced Transdermal Fluid Removal (TFR) technology which enables the extraction of excess fluid through the skin using disposable micro-needle patches and overcomes many of the issues with current treatments.
The company is a spin out of The University of Manchester and Manchester University NHS Foundation Trust by UMI3 Ltd.